Molbio Diagnostics Q2 FY27 Earnings Call: Reaffirms 25% Growth Guidance, Rs. 100 Cr Shifted to H2

Molbio Diagnostics Ltd held its Q2 FY27 earnings call on November 05, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Flat H1 on a Timing Slip; Margins Absorb OptraScan Drag

• H1 FY 2026-2027 consolidated revenue of Rs.667 crore — vs Rs.680 crore in H1 FY 2025-2026, slightly softer than the FY 2026-2027 plan; export revenue was ~Rs.120 crore in H1 FY 2026-2027.
• H1 volumes of 559 devices and 94.7 lakh kits — sold in H1 FY 2026-2027.
• H1 EBITDA of Rs.153 crore (23% margin) — includes a Rs.15 crore EBITDA loss (~2.2% of revenue) from OptraScan, which became a subsidiary only in H2 FY 2025-2026 and was absent from the prior-year base.
• H1 PAT of Rs.60 crore, softer YoY — primarily due to additional interest cost on the OptraScan acquisition term loan and amortization of acquired intangibles.
• Balance sheet swung to net cash as of September 2026 — from net debt/borrowings of Rs.57 crore as of March 2026 (FY 2025-2026 end), lifting interest income and lowering interest expense in Q2 vs Q1 FY 2026-2027.
• Receivable days improved to 77 (trailing 12 months) — inventory turnover at 1.2x, in line with FY 2025-2026.

~Rs.100 Cr Shifted to H2; Pricing Intact, Guidance Reaffirmed

• ~Rs.100 crore of revenue deferred from H1 to H2 FY 2026-2027 — due to a ~one-month delay in concluding the government rate contract renewal; the CEO framed it as a timing shift, not a demand change, with FY 2026-2027 procurement/requirement unaffected.
• Delay attributed to the government's general body meeting being pushed — a normal-course occurrence in the rate-contract process; the renewal had been flagged on the previous earnings call, but its duration was not anticipated. The rate contract is now secured, orders are in hand and supplies are underway.
• No pricing pressure — the CFO said realization under the new rate contract is similar to FY 2025-2026 and "in line"; Q2 FY 2026-2027 average realizations were better than Q1 on product mix.
• Seasonality pattern reiterated — the public-health business typically books 40% of revenue in H1 and 60% in H2 (management also cited a historical 35-45% H1 range, "which is the case" for H1 FY 2026-2027).
• Procurement mechanics explained — even proprietary/single-bidder purchases require tendering; the government freezes pricing and awards a two-year rate contract, releasing orders at regular intervals. Order-to-cash runs a 2-month supply window plus ~30-45 days after documentation, with invoice-to-payment realization currently at ~60-75 days.
• Installed base underpins demand — close to 10,000 TrueNat machines installed in government primary centers as of Q2 FY 2026-2027, which management said means captive kit consumption is effectively assured.

TruePOC, TrueAmp, TrueSight: Royalty-Free, Global-First

• Three new platforms fully developed in-house with no royalty obligations — CEO Sriram Natarajan confirmed no external partners; CTO Chandrashekhar Nair acknowledged Gates Foundation support for TruePOC's development with no royalties payable to the foundation.
• TrueAmp launches with five syndrome panels — respiratory, STI, HPV genotyping, sepsis and antimicrobial resistance; management noted US company BioFire already offers multiplex syndromic testing at a cost unaffordable for India, and Molbio designed its platform for affordability in developing markets.
• TrueSight targets the doctor's office — finger-prick sample yields cell morphology/count results during the consultation, removing the current ~1-day wait for lab reports; leverages AI and is intended to eventually flag abnormalities beyond what a molecular test can reveal.
• Regulatory path: CDSCO license first — studies ongoing with management estimating completion in ~4-5 months (period unspecified), unlocking India launch and country-by-country export registrations.
• Global launch committed, explicitly not India-first — products expected to scale over 2-3 years (period unspecified), with business beginning at launch in India and faster-registration markets.
• Go-to-market split by channel — TrueAmp focuses on the private sector leveraging ~1,200 TrueNAT devices placed as of Q2 FY 2026-2027 plus a new private-sector BD team; TruePOC sells via the public health space; TrueSight may potentially see pharma tie-ups.

Market Creation in an Unorganized Segment; FY28 Assay Ramp

• Veterinary portfolio of 7 assays, 1 (rabies) already in market — CFO Manan Kokani said initial focus is pet companion diseases (parvo, canine distemper, leptospirosis) before bovine and shrimp; of the remaining 6, 2 are in development/testing with 4 to begin thereafter, expected to come to market in FY28.
• Market is unorganized with no molecular testing sizing available — the CFO noted most testing happens at human clinics, samples are sent to centralized labs (which becomes very expensive), and molecular testing at the vet clinic level is not happening today.
• Management is looking to create a new market rather than displace competitors — no market share target was provided for the analyst's 3-5 year horizon question; first phase focuses on companion pets (dogs and cats).
• No notifiability provision on the veterinary side — the CEO clarified there are no notifiable diseases in veterinary as of now (bird flu is a problem but not notifiable); the government will do surveillance and monitoring, unlike human diagnostics (TB, COVID).
• Radiology already launched with good traction — regular and ultra-portable X-rays serve pets and horses; the onboarded veterinary team will also sell veterinary applications on TrueNAT and TrueSight across India and globally; management indicated veterinary will scale gradually rather than deliver significant business immediately.

Modest H2 Pickup, Real Ramp from FY 2027-2028

• OptoScan USFDA approval received ~2.5 months before the call — Molbio owns a 60% stake in US subsidiary OptoScan; clinical studies have started running within large laboratory networks in the US.
• CEO expects only a modest OptoScan pickup in H2 FY 2026-2027 — with the "real action" and good uptake probably starting from FY 2027-2028, consistent with the original plan and no change in approach or expectations.
• Export outlook "looking great" — significantly more export activity expected in H2 FY 2026-2027, addressing the analyst's observation that export pickup has been weak for a couple of years.
• Two export streams — consumables for the existing installed base plus new requirements, and new machine requirements operating on the Global Fund cycle; cycle projections are kicking in now, so more machine procurement is expected in H2 FY 2026-2027.
• WHO's role is advocacy only — the CEO stated WHO "will not specifically promote Molbio's product, as that is not in its mandate"; in Africa, procurement happens mostly through the Global Fund, where Molbio is on the list and the Global Fund encourages countries to request TrueNAT; the key adoption hurdle is programmatic uptake and continuity of funding.

FY27 Targets Reiterated; Automation Supports ~3x Revenue Capacity

• FY 2026-2027 guidance reiterated at call close — management (via IR head Indraneel Borkakoti) reaffirmed 25% top line growth and a 24-25% EBITDA margin target for FY 2026-2027, stating it is on track; guidance is given on a yearly basis (no multi-year 25% commitment for FY 2027-2028 onward).
• IPO raised ~Rs.200 crore fresh capital, ~Rs.72 crore earmarked for automation — purchase orders for automation equipment already placed; management believes this capacity can support ~3x the earlier ~Rs.1,000 crore top line guidance (≈Rs.3,000 crore) (period unspecified) with no further capex needed "to that extent" for capacity.
• Utilization at ~58% for kits and ~42% for devices — as of Q2 FY 2026-2027, per the analyst's framing (Dhanraj Tolaj, Kuber Advisors).
• Three growth levers to scale in parallel over the next 2-3 years (FY 2027-2028 onward) — microscopy-to-molecular conversion, TrueNat share gains within molecular, and new products/non-TB tests/exports, with none cannibalizing the others; hepatitis is already contributing as of Q2 FY 2026-2027 and the HPV launch is "likely to start soon" (timing unspecified).
• New product launches expected one after another over the next 3-4 months (H2 FY 2026-2027) — R&D pipeline in final stage with products ready for validation; TruQoQ swab-based screening test is close to launch, going into validation soon.
• Management expects the combination of existing growth, geographic expansion and new verticals to take the company "to a different level" in FY 2027-2028 — though H1 FY 2026-2027 came in slightly softer than plan and PAT was pressured by OptraScan-related interest and amortization costs.